Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Given Consensus Rating of “Moderate Buy” by Brokerages

Shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) have received a consensus rating of “Moderate Buy” from the six ratings firms that are covering the stock, MarketBeat.com reports. Two research analysts have rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokerages that have issued ratings on the stock in the last year is $52.50.

A number of research firms have recently weighed in on ETON. HC Wainwright upped their price target on shares of Eton Pharmaceuticals from $52.00 to $57.00 and gave the stock a “buy” rating in a research note on Friday, May 15th. Wall Street Zen raised Eton Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research note on Friday, July 17th. Craig Hallum upped their target price on Eton Pharmaceuticals from $40.00 to $62.00 and gave the stock a “buy” rating in a research report on Tuesday, July 28th. Finally, Canaccord Genuity Group began coverage on Eton Pharmaceuticals in a research report on Thursday, July 16th. They issued a “buy” rating and a $60.00 target price on the stock.

Eton Pharmaceuticals Stock Performance

Shares of ETON opened at $43.67 on Thursday. The company’s 50 day moving average price is $37.66 and its 200 day moving average price is $27.82. Eton Pharmaceuticals has a 52 week low of $14.27 and a 52 week high of $50.18. The company has a market capitalization of $1.20 billion, a PE ratio of -623.77 and a beta of 0.86. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.88 and a current ratio of 1.21.

Eton Pharmaceuticals (NASDAQ:ETON) last released its quarterly earnings data on Thursday, May 14th. The company reported $0.05 earnings per share for the quarter, missing the consensus estimate of $0.10 by ($0.05). The company had revenue of $24.27 million during the quarter, compared to analyst estimates of $22.31 million. Eton Pharmaceuticals had a negative net margin of 1.70% and a negative return on equity of 5.68%. Research analysts expect that Eton Pharmaceuticals will post 0.75 EPS for the current fiscal year.

Insider Activity at Eton Pharmaceuticals

In related news, Director Jennifer Mckie Adams sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $32.48, for a total value of $1,624,000.00. Following the completion of the sale, the director owned 50,000 shares of the company’s stock, valued at approximately $1,624,000. The trade was a 50.00% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider David Krempa sold 19,679 shares of the stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $31.47, for a total value of $619,298.13. Following the completion of the transaction, the insider owned 25,249 shares in the company, valued at $794,586.03. This represents a 43.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 150,000 shares of company stock valued at $4,853,921. 16.49% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. Quarry LP bought a new stake in Eton Pharmaceuticals in the third quarter worth $37,000. Persistent Asset Partners Ltd bought a new position in Eton Pharmaceuticals during the second quarter valued at about $90,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Eton Pharmaceuticals in the fourth quarter worth about $44,000. Legal & General Group Plc acquired a new stake in shares of Eton Pharmaceuticals in the second quarter worth about $41,000. Finally, State of Wyoming bought a new stake in shares of Eton Pharmaceuticals during the 2nd quarter worth about $107,000. Institutional investors and hedge funds own 27.86% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.